Biotechnology company scientists Anixa Biosciences Promising results were announced for a new vaccine that could prevent the recurrence of the most aggressive cases of breast cancer. In the first phase of the clinical study, all volunteers produced strong immune responses against the tumor.

The vaccine is designed to direct the immune system to destroy triple-negative breast cancer (TNBC) cancer cells through an innovative mechanism. TNBC is an aggressive type of breast cancer that has no hormone receptors and does not produce a protein known as HER2.

Read more:

Most available oncology treatments focus on targeting hormone receptors or the HER2 protein, which reduces the effectiveness of TNBC treatments. Furthermore, this type of tumor tends to grow faster, making it more aggressive.

Study and clinical results

• In the first clinical tests, 16 women already treated for triple-negative breast cancer received the vaccine developed by Anixa;
• Three doses of the vaccine were given, with an interval of two weeks between each dose.
• The results showed promising immune responses, measured by T and B lymphocyte counts;
• T-cell response was observed in 75% of patients, while B-lymphocyte production was found at higher concentrations of vaccine;
• Reported adverse effects were mild, highlighting irritation at the application site as the most common.

The study was presented during the San Antonio Breast Cancer Symposium, held in the United States in 2023. However, the results have not yet been published in scientific journals and have not been subject to peer review.

Anixa Biosciences plans to conduct a new clinical study to evaluate the effects of the vaccine in combination with the drug Keytruda, used to treat various types of cancer. This research will open new horizons and potential developments in the field of cancer immunotherapy.